Rabies post exposure prophylaxis, or PEP, consists of a rabies vaccine series and human rabies immune globulin (HRIG).
Kedrion Biopharma’s human rabies immune globulin, Kedrab, was FDA approved in 2017. And now for the first time, the safety of HRIG (Kedrab) was studied in children.
Joining me today to discuss rabies, PEP and the pediatric trial is James Linakis, MD, PhD. Dr. Linakis is Professor of Emergency Medicine and Pediatrics at Brown Medical School and Associate Director of Pediatric Emergency Medicine at Rhode Island Hospital’s Hasbro Children’s Hospital.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Stitcher | RSS
Related:
Rabies and Travel Health with Dr. Jonas Nilsen
Rabies: Signs and symptoms, exposure, transmission and diagnostics
Rabies in the US: Geography, wildlife, exposure and prevention
Zoonotic diseases in the US: Rabies, Lyme disease among eight of most concern
Rabies: The fatal Virginia case and some important lessons
Rabies: What should you do if you’re exposed?
Rabies death reported in Utah, First since 1944
Rabies: History, myths and diagnosis on Outbreak News This Week
2 thoughts on “Kedrab: 1st pediatric trial for Human Rabies Immune Globulin”